HMG-CoA-Reductase inhibitors (HMGRIs; also commonly referred to as statins) are the most widely used lipid-lowering medication for the majority of people with CHD risk, including those with diabetes mellitus type 2 (DM) (Knuuti et al. 2020). The gene discussed is HMGCR; the disease is diabetes mellitus.